Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			$ 63,284
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 78,174
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			1,214
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		9 days
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 398
Oragenics, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			5,810
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 10 months 24 days
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 5,552
Intrexon Energy Partners, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			10,267
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 9 months 18 days
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 9,059
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			14,060
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		5 years 4 months 24 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 13,136
Surterra Holdings, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			0
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		9 years
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 14,500
Genopaver, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			1,175
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 9 months 18 days
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 1,162
Fibrocell Science, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			17,519
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		5 years 4 months 24 days
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 18,507
Persea Bio, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			2,697
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		5 years 6 months
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 3,839
Harvest start-up entities | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	[1]		7,644
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	[1]	5 years 8 months 12 days
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	[1]	$ 6,993
Other | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			$ 2,898
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		1 year 9 months 18 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 5,028

[1] As of June 30, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.